Loading...
XNASBNTX
Market cap27bUSD
Dec 23, Last price  
113.51USD
1D
0.38%
1Q
-4.19%
IPO
721.35%
Name

BioNTech SE

Chart & Performance

D1W1MN
XNAS:BNTX chart
P/E
28.11
P/S
6.85
EPS
3.88
Div Yield, %
0.00%
Shrs. gr., 5y
1.36%
Rev. gr., 5y
97.35%
Revenues
3.82b
-77.94%
61,598,000127,575,000108,589,000482,325,00018,976,700,00017,310,600,0003,819,000,000
Net income
930m
-90.14%
-85,653,000-48,019,000-179,172,00015,200,00010,292,500,0009,434,400,000930,300,000
CFO
5.37b
-60.44%
-52,562,000-58,180,000-198,537,000-13,474,000889,700,00013,577,400,0005,371,400,000
Dividend
Jun 02, 20222.26067 USD/sh
Earnings
May 16, 2025

Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
IPO date
Oct 10, 2019
Employees
5,500
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
3,819,000
-77.94%
17,310,600
-8.78%
18,976,700
3,834.42%
Cost of revenue
2,940,600
5,192,200
4,292,300
Unusual Expense (Income)
NOPBT
878,400
12,118,400
14,684,400
NOPBT Margin
23.00%
70.01%
77.38%
Operating Taxes
255,800
3,519,700
4,753,900
Tax Rate
29.12%
29.04%
32.37%
NOPAT
622,600
8,598,700
9,930,500
Net income
930,300
-90.14%
9,434,400
-8.34%
10,292,500
67,613.82%
Dividends
(475,578)
Dividend yield
1.27%
Proceeds from repurchase of equity
(738,500)
(877,890)
160,900
BB yield
2.88%
2.34%
-0.24%
Debt
Debt current
36,000
129,900
Long-term debt
568,355
212,200
325,376
Deferred revenue
48,400
9,000
Other long-term liabilities
310,300
42,100
208,200
Net debt
(17,156,745)
(13,896,500)
(1,640,324)
Cash flow
Cash from operating activities
5,371,400
13,577,400
889,700
CAPEX
(250,100)
(363,300)
(154,000)
Cash from investing activities
(6,954,500)
(35,300)
(566,100)
Cash from financing activities
(778,600)
(1,419,300)
94,200
FCF
3,981,700
12,952,900
138,256
Balance
Cash
16,549,000
14,064,500
2,074,300
Long term investments
1,176,100
80,200
21,300
Excess cash
17,534,150
13,279,170
1,146,765
Stockholders' equity
20,256,700
20,060,900
11,897,500
Invested Capital
3,401,650
6,483,230
9,696,735
ROIC
12.60%
106.29%
171.88%
ROCE
4.20%
61.30%
134.59%
EV
Common stock shares outstanding
242,700
249,800
259,700
Price
105.54
-29.74%
150.22
-41.73%
257.80
216.24%
Market cap
25,614,558
-31.74%
37,524,956
-43.95%
66,950,660
230.46%
EV
8,457,813
23,628,456
65,310,336
EBITDA
1,061,800
12,241,700
14,759,600
EV/EBITDA
7.97
1.93
4.42
Interest
7,900
18,900
5,400
Interest/NOPBT
0.90%
0.16%
0.04%